The company plans to issue its financial report at 1:00 p.m. Pacific Time, followed by a live conference call and webcast at 1:30 p.m. Pacific Time. Participants joining from the United States may dial 800-347-6865, while international callers should use 203-518-9757, referencing the conference ID NBIX. A digital broadcast will be available through the investor relations section of the company's website, with an archived replay accessible for one month starting shortly after the event concludes. Neurocrine currently maintains a portfolio focused on neurological, psychiatric, and endocrine disorders, including FDA-approved treatments for tardive dyskinesia and Huntington’s disease-related chorea.
Neurocrine Biosciences Sets November 2 for Third Quarter Earnings
Investors will receive a look at Neurocrine Biosciences' financial performance on November 2, 2026, as the San Diego-based biopharmaceutical firm prepares to host its third-quarter earnings call. The session follows the release of the company's quarterly results, scheduled for earlier that same afternoon.
Comments (0)
No comments yet. Be the first!